Celldex Therapeutics (CLDX) Net Cash Flow (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Net Cash Flow of $6.8 million for Q1 2026, up 161.02% year-over-year from $2.6 million in Q1 2025, and up 195.47% quarter-over-quarter from -$7.2 million in Q4 2025.
Celldex Therapeutics (CLDX) Net Cash Flow (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 161.02% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $18.6 million (up 118.97% YoY), while the FY2025 annual figure was $515000.0, up 107.97% from the prior year.
- Net Cash Flow for Q1 2026 stood at $6.8 million, up from -$7.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $80.3 million in Q1 2024, with the low at -$72.3 million in Q2 2024.
- The 5-year median for Net Cash Flow is -$6.3 million (2024), against an average of -$201529.4.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 933.3% in 2023, then soared 305.02% in 2025.
- Celldex Therapeutics' Net Cash Flow stood at $10.8 million in 2022, then rose by 26.13% to $13.7 million in 2023, then sank by 158.79% to -$8.0 million in 2024, then climbed by 10.84% to -$7.2 million in 2025, then jumped by 195.47% to $6.8 million in 2026.
- Business Quant data shows CLDX's Net Cash Flow at $6.8 million in Q1 2026, -$7.2 million in Q4 2025, and $13.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 11.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.74 Mn |
| Jun 30, 2026 | 11.74 Mn |
| Mar 31, 2026 | 6.85 Mn |
| Mar 31, 2026 | 6.85 Mn |
| Dec 31, 2025 | -7.17 Mn |
| Dec 31, 2025 | -7.17 Mn |
| Sep 30, 2025 | 13.00 Mn |
| Sep 30, 2025 | 13.00 Mn |
| Jun 30, 2025 | 5.91 Mn |
| Jun 30, 2025 | 5.91 Mn |
| Mar 31, 2025 | -11.22 Mn |
| Mar 31, 2025 | -11.22 Mn |
| Dec 31, 2024 | -8.04 Mn |
| Dec 31, 2024 | -8.04 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -72.34 Mn |
| Jun 30, 2024 | -72.34 Mn |
| Mar 31, 2024 | 80.26 Mn |
| Mar 31, 2024 | 80.26 Mn |